Shopping Cart 0
Cart Subtotal
USD 0

Esophageal Cancer - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Esophageal Cancer-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer-Pipeline Review, H2 2018, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.

Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 46, 45, 3, 26 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 3 and 2 molecules, respectively.

Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 6

Esophageal Cancer-Overview 7

Esophageal Cancer-Therapeutics Development 8

Esophageal Cancer-Therapeutics Assessment 26

Esophageal Cancer-Companies Involved in Therapeutics Development 40

Esophageal Cancer-Drug Profiles 77

Esophageal Cancer-Dormant Projects 747

Esophageal Cancer-Discontinued Products 752

Esophageal Cancer-Product Development Milestones 753

Appendix 764


List Of Figure

List of Figures

Number of Products under Development for Esophageal Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Esophageal Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Esophageal Cancer-Pipeline by AbbVie Inc, H2 2018

Esophageal Cancer-Pipeline by Adaptimmune Therapeutics Plc, H2 2018

Esophageal Cancer-Pipeline by Advenchen Laboratories LLC, H2 2018

Esophageal Cancer-Pipeline by Ambrx Inc, H2 2018

Esophageal Cancer-Pipeline by amcure GmbH, H2 2018

Esophageal Cancer-Pipeline by AMI Onco Theranostics LLC, H2 2018

Esophageal Cancer-Pipeline by Apexigen Inc, H2 2018

Esophageal Cancer-Pipeline by Aprea AB, H2 2018

Esophageal Cancer-Pipeline by AVEO Pharmaceuticals Inc, H2 2018

Esophageal Cancer-Pipeline by Bayer AG, H2 2018

Esophageal Cancer-Pipeline by BeiGene Ltd, H2 2018

Esophageal Cancer-Pipeline by BioStar Pharmaceuticals Inc, H2 2018

Esophageal Cancer-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Esophageal Cancer-Pipeline by Bristol-Myers Squibb Co, H2 2018

Esophageal Cancer-Pipeline by Cantargia AB, H2 2018

Esophageal Cancer-Pipeline by CBT Pharmaceuticals Inc, H2 2018

Esophageal Cancer-Pipeline by Celgene Corp, H2 2018

Esophageal Cancer-Pipeline by Celldex Therapeutics Inc, H2 2018

Esophageal Cancer-Pipeline by Cristal Therapeutics BV, H2 2018

Esophageal Cancer-Pipeline by CSPC Pharmaceutical Group Limited, H2 2018

Esophageal Cancer-Pipeline by Cyclacel Pharmaceuticals Inc, H2 2018

Esophageal Cancer-Pipeline by CytomX Therapeutics Inc, H2 2018

Esophageal Cancer-Pipeline by DAE HWA Pharmaceutical Co Ltd, H2 2018

Esophageal Cancer-Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Esophageal Cancer-Pipeline by Eli Lilly and Co, H2 2018

Esophageal Cancer-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Esophageal Cancer-Pipeline by FLX Bio Inc, H2 2018

Esophageal Cancer-Pipeline by Genmab A/S, H2 2018

Esophageal Cancer-Pipeline by GlaxoSmithKline Plc, H2 2018

Esophageal Cancer-Pipeline by Glycotope GmbH, H2 2018

Esophageal Cancer-Pipeline by Guangzhou Saliai Stemcell Science and Technology Co Ltd, H2 2018

Esophageal Cancer-Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018

Esophageal Cancer-Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, H2 2018

Esophageal Cancer-Pipeline by Hutchison MediPharma Ltd, H2 2018

Esophageal Cancer-Pipeline by Idera Pharmaceuticals Inc, H2 2018

Esophageal Cancer-Pipeline by Immunocore Ltd, H2 2018

Esophageal Cancer-Pipeline by Immunomedics Inc, H2 2018

Esophageal Cancer-Pipeline by Incyte Corp, H2 2018

Esophageal Cancer-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Esophageal Cancer-Pipeline by Johnson & Johnson, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Esophageal Cancer Therapeutic Products under Development, Key Players in Esophageal Cancer Therapeutics, Esophageal Cancer Pipeline Overview, Esophageal Cancer Pipeline, Esophageal Cancer Pipeline Assessment


Companies

AbbVie Inc

Adaptimmune Therapeutics Plc

Advenchen Laboratories LLC

Ambrx Inc

amcure GmbH

AMI Onco Theranostics LLC

Apexigen Inc

Aprea AB

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

BioStar Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cantargia AB

CBT Pharmaceuticals Inc

Celgene Corp

Celldex Therapeutics Inc

Cristal Therapeutics BV

CSPC Pharmaceutical Group Limited

Cyclacel Pharmaceuticals Inc

CytomX Therapeutics Inc

DAE HWA Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

FLX Bio Inc

Genmab A/S

GlaxoSmithKline Plc

Glycotope GmbH

Guangzhou Saliai Stemcell Science and Technology Co Ltd

Hanmi Pharmaceuticals Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

Hutchison MediPharma Ltd

Idera Pharmaceuticals Inc

Immunocore Ltd

Immunomedics Inc

Incyte Corp

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Kura Oncology Inc

Leap Therapeutics Inc

LIfT BioSciences Ltd

Lycera Corp

MaxCyte Inc

MaxiVAX SA

Mebiopharm Co Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

MetaMax Ltd

Millennium Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

Moderna Therapeutics Inc

Novartis AG

Omeros Corp

Omnitura Therapeutics Inc

Oncolys BioPharma Inc

OncoMed Pharmaceuticals Inc

Onconova Therapeutics Inc

Ono Pharmaceutical Co Ltd

Pieris Pharmaceuticals Inc

Puma Biotechnology Inc

Replimune Ltd

Revolution Medicines Inc

Rhizen Pharmaceuticals SA

Scancell Holdings Plc

Seattle Genetics Inc

Shionogi & Co Ltd

Sino Biopharmaceutical Ltd

Soricimed Biopharma Inc

Steba Biotech SA

Supratek Pharma Inc

Taiho Pharmaceutical Co Ltd

Takara Bio Inc

Takeda Pharmaceutical Co Ltd

Transgene Biotek Ltd

Transgene SA

Tyg Oncology Ltd

XuanZhu Pharma Co Ltd

Esophageal Cancer-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer-Pipeline Review, H2 2018, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.

Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 46, 45, 3, 26 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 3 and 2 molecules, respectively.

Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 6

Esophageal Cancer-Overview 7

Esophageal Cancer-Therapeutics Development 8

Esophageal Cancer-Therapeutics Assessment 26

Esophageal Cancer-Companies Involved in Therapeutics Development 40

Esophageal Cancer-Drug Profiles 77

Esophageal Cancer-Dormant Projects 747

Esophageal Cancer-Discontinued Products 752

Esophageal Cancer-Product Development Milestones 753

Appendix 764


List Of Figure

List of Figures

Number of Products under Development for Esophageal Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Esophageal Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Esophageal Cancer-Pipeline by AbbVie Inc, H2 2018

Esophageal Cancer-Pipeline by Adaptimmune Therapeutics Plc, H2 2018

Esophageal Cancer-Pipeline by Advenchen Laboratories LLC, H2 2018

Esophageal Cancer-Pipeline by Ambrx Inc, H2 2018

Esophageal Cancer-Pipeline by amcure GmbH, H2 2018

Esophageal Cancer-Pipeline by AMI Onco Theranostics LLC, H2 2018

Esophageal Cancer-Pipeline by Apexigen Inc, H2 2018

Esophageal Cancer-Pipeline by Aprea AB, H2 2018

Esophageal Cancer-Pipeline by AVEO Pharmaceuticals Inc, H2 2018

Esophageal Cancer-Pipeline by Bayer AG, H2 2018

Esophageal Cancer-Pipeline by BeiGene Ltd, H2 2018

Esophageal Cancer-Pipeline by BioStar Pharmaceuticals Inc, H2 2018

Esophageal Cancer-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Esophageal Cancer-Pipeline by Bristol-Myers Squibb Co, H2 2018

Esophageal Cancer-Pipeline by Cantargia AB, H2 2018

Esophageal Cancer-Pipeline by CBT Pharmaceuticals Inc, H2 2018

Esophageal Cancer-Pipeline by Celgene Corp, H2 2018

Esophageal Cancer-Pipeline by Celldex Therapeutics Inc, H2 2018

Esophageal Cancer-Pipeline by Cristal Therapeutics BV, H2 2018

Esophageal Cancer-Pipeline by CSPC Pharmaceutical Group Limited, H2 2018

Esophageal Cancer-Pipeline by Cyclacel Pharmaceuticals Inc, H2 2018

Esophageal Cancer-Pipeline by CytomX Therapeutics Inc, H2 2018

Esophageal Cancer-Pipeline by DAE HWA Pharmaceutical Co Ltd, H2 2018

Esophageal Cancer-Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Esophageal Cancer-Pipeline by Eli Lilly and Co, H2 2018

Esophageal Cancer-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Esophageal Cancer-Pipeline by FLX Bio Inc, H2 2018

Esophageal Cancer-Pipeline by Genmab A/S, H2 2018

Esophageal Cancer-Pipeline by GlaxoSmithKline Plc, H2 2018

Esophageal Cancer-Pipeline by Glycotope GmbH, H2 2018

Esophageal Cancer-Pipeline by Guangzhou Saliai Stemcell Science and Technology Co Ltd, H2 2018

Esophageal Cancer-Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018

Esophageal Cancer-Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, H2 2018

Esophageal Cancer-Pipeline by Hutchison MediPharma Ltd, H2 2018

Esophageal Cancer-Pipeline by Idera Pharmaceuticals Inc, H2 2018

Esophageal Cancer-Pipeline by Immunocore Ltd, H2 2018

Esophageal Cancer-Pipeline by Immunomedics Inc, H2 2018

Esophageal Cancer-Pipeline by Incyte Corp, H2 2018

Esophageal Cancer-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Esophageal Cancer-Pipeline by Johnson & Johnson, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Esophageal Cancer Therapeutic Products under Development, Key Players in Esophageal Cancer Therapeutics, Esophageal Cancer Pipeline Overview, Esophageal Cancer Pipeline, Esophageal Cancer Pipeline Assessment


Companies

AbbVie Inc

Adaptimmune Therapeutics Plc

Advenchen Laboratories LLC

Ambrx Inc

amcure GmbH

AMI Onco Theranostics LLC

Apexigen Inc

Aprea AB

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

BioStar Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cantargia AB

CBT Pharmaceuticals Inc

Celgene Corp

Celldex Therapeutics Inc

Cristal Therapeutics BV

CSPC Pharmaceutical Group Limited

Cyclacel Pharmaceuticals Inc

CytomX Therapeutics Inc

DAE HWA Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

FLX Bio Inc

Genmab A/S

GlaxoSmithKline Plc

Glycotope GmbH

Guangzhou Saliai Stemcell Science and Technology Co Ltd

Hanmi Pharmaceuticals Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

Hutchison MediPharma Ltd

Idera Pharmaceuticals Inc

Immunocore Ltd

Immunomedics Inc

Incyte Corp

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Kura Oncology Inc

Leap Therapeutics Inc

LIfT BioSciences Ltd

Lycera Corp

MaxCyte Inc

MaxiVAX SA

Mebiopharm Co Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

MetaMax Ltd

Millennium Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

Moderna Therapeutics Inc

Novartis AG

Omeros Corp

Omnitura Therapeutics Inc

Oncolys BioPharma Inc

OncoMed Pharmaceuticals Inc

Onconova Therapeutics Inc

Ono Pharmaceutical Co Ltd

Pieris Pharmaceuticals Inc

Puma Biotechnology Inc

Replimune Ltd

Revolution Medicines Inc

Rhizen Pharmaceuticals SA

Scancell Holdings Plc

Seattle Genetics Inc

Shionogi & Co Ltd

Sino Biopharmaceutical Ltd

Soricimed Biopharma Inc

Steba Biotech SA

Supratek Pharma Inc

Taiho Pharmaceutical Co Ltd

Takara Bio Inc

Takeda Pharmaceutical Co Ltd

Transgene Biotek Ltd

Transgene SA

Tyg Oncology Ltd

XuanZhu Pharma Co Ltd